Oskar Hagberg

Medicine and Dentistry

1. Patient 100%
2. Bladder Cancer 95%
3. Cystectomy 52%
4. Therapeutic Procedure 41%
5. Surgery 28%
6. Base 24%
7. Age 18%
8. Cumulative Incidence 18%
9. Follow up 15%
10. Gender 14%
11. Hazard Ratio 13%
12. Hospital 12%
13. Lymph Node Metastasis 11%
14. Patient Referral 11%
15. Cohort Analysis 10%
16. Lymph Node 9%
17. Microhematuria 9%
18. Childhood Cancer 9%
19. Diffuse Large B-Cell Lymphoma 9%
20. Breast Cancer 9%
21. Non Muscle Invasive Bladder Cancer 9%
22. Transitional Cell Carcinoma 9%
23. Association 9%
24. Overall Survival 9%
25. Bladder 8%
26. Retroperitoneal Lymph Node Dissection 8%
27. Proportional Hazards Model 8%
28. Comorbidity 7%
29. Cancer 7%
30. Health 7%
31. Man 6%
32. Cancer Diagnosis 6%
33. Primary Tumor 6%
34. Mycobacterium Bovis BCG 6%
35. Woman 6%
36. Mortality 6%
37. False Positive Result 6%
38. Intervention Study 6%
39. Second Cancer 6%
40. Urinary Diversion 5%
41. Death 5%
42. Thromboembolism 5%
43. Stricture 5%
44. Incisional Hernia 5%
45. Prognosis 5%
46. Cancer Mortality 5%
47. International Prognostic Index 5%
48. Upper Urinary Tract 5%
49. Ileal Conduit 5%